These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38191946)

  • 1. Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study.
    Jaarah N; Lam CFJ; Lodhia N; Dulnoan D; Moore AE; Hampson G
    J Endocrinol Invest; 2024 Jul; 47(7):1667-1677. PubMed ID: 38191946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
    Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
    Mok J; Brown C; Moore AEB; Min SS; Hampson G
    Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.
    Dito G; Lugaresi M; Degradi C; Guabello G; Longhi M; Corbetta S
    Endocrine; 2023 Oct; 82(1):181-189. PubMed ID: 37402061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis.
    Ebina K; Hashimoto J; Kashii M; Hirao M; Miyama A; Nakaya H; Tsuji S; Takahi K; Tsuboi H; Okamura G; Etani Y; Takami K; Yoshikawa H
    Mod Rheumatol; 2021 Mar; 31(2):485-492. PubMed ID: 32412351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: a 'real-life' study.
    Fraser TR; Flogaitis I; Moore AE; Hampson G
    J Endocrinol Invest; 2020 Apr; 43(4):469-475. PubMed ID: 31664706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
    J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
    Clifton Goldney D; Pelegrin C; Jerkovich F; Longobardi V; Gonzalez Rodriguez E; Zanchetta MB
    Osteoporos Int; 2024 Jan; 35(1):165-171. PubMed ID: 37702746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of differences in dose and frequency of teriparatide on bone structure in Proximal Femur. - Analysis by DXA-based 3D-modeling (3D-SHAPER Software) -TRIPLE-BONE study (The effects of TeRIParatide preparation on bone mineraL density increase and BONE structure).
    Takada J; Okimoto N; Tsukamoto M; Akatsuka T; Takebayashi T; Iba K; Ikeda S
    Arch Osteoporos; 2024 Jul; 19(1):55. PubMed ID: 38954145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis.
    Sone T; Kon N; Gaither KW; Okubo N; Osakabe T; Nakayama Y; Fukunaga M; Ito M; Nakamura T
    Bone Rep; 2017 Dec; 7():164-171. PubMed ID: 29188222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
    Sølling AS; Harsløf T; Langdahl B
    J Bone Miner Res; 2021 Jul; 36(7):1245-1254. PubMed ID: 33813753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
    Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM
    Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
    Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
    Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abaloparatide Effects on Cortical Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women With Postmenopausal Osteoporosis.
    Winzenrieth R; Humbert L; Boxberger JI; Weiss RJ; Wang Y; Kostenuik P
    J Clin Densitom; 2022; 25(3):392-400. PubMed ID: 35033435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
    Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
    J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of monthly ibandronate on hip structural geometry in men with low bone density.
    Genant HK; Lewiecki EM; Fuerst T; Fries M
    Osteoporos Int; 2012 Jan; 23(1):257-65. PubMed ID: 21811866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: A single center cross-sectional study.
    Pedersini R; Cosentini D; Rinaudo L; Zamparini M; Ulivieri FM; di Mauro P; Maffezzoni F; Monteverdi S; Vena W; Laini L; Amoroso V; Simoncini EL; Farina D; Mazziotti G; Berruti A
    Bone Rep; 2023 Jun; 18():101654. PubMed ID: 36700242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
    Miyagi M; Fujimaki H; Naruse K; Suto K; Inoue G; Nakazawa T; Imura T; Saito W; Uchida K; Shirasawa E; Takahira N; Takaso M
    J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.
    Makras P; Appelman-Dijkstra NM; Papapoulos SE; van Wissen S; Winter EM; Polyzos SA; Yavropoulou MP; Anastasilakis AD
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e4155-e4162. PubMed ID: 33978745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.